Companies › Minerva Neurosciences
1 active drug program in 1 registered trial: 1 Phase 3; Psychiatry; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Roluperidone (MIN-101) Trace amine-associated receptor 1 (TAAR1) agonist | TAAR1 | Phase 3 | Negative Symptoms of Schizophrenia | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07565428 | Roluperidone (MIN-101) | Phase 3 | Negative Symptoms of Schizophrenia | Psychiatry | Dec 2027 |
Cash and short-term investments of $77m on 2026-09-30; operating cash outflow about $36m a year; runway about 26 months at that burn, to Nov 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
LB Pharmaceuticals Reviva Pharmaceuticals Curemark Emalex Biosciences Boston Medical Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.